//
The year in cardiovascular medicine 2020: heart failure and cardiomyopathies
A Fully Magnetically Levitated Left Ventricular Assist Device — Final Report
Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction
Sex Differences in Heart Failure With Preserved Ejection Fraction Pathophysiology: A Detailed Invasive Hemodynamic and Echocardiographic Analysis
Permanent pacemaker use among patients with heart failure and preserved ejection fraction: Findings from the Acute Decompensated Heart Failure National Registry (ADHERE) National Registry
Risk of Mortality Following Catheter Ablation of Atrial Fibrillation
Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)